[HTML][HTML] Preclinical models in prostate cancer: Resistance to AR targeting therapies in prostate cancer
Simple Summary In this review, we will look into the existing methods to study treatment
resistance to androgen receptor targeted therapies in prostate cancer. This will encompass …
resistance to androgen receptor targeted therapies in prostate cancer. This will encompass …
Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer.
W Devlies, F Handle, G Devos, S Joniau… - …, 2021 - search.ebscohost.com
Abstract Simple Summary: In this review, we will look into the existing methods to study
treatment resistance to androgen receptor targeted therapies in prostate cancer. This will …
treatment resistance to androgen receptor targeted therapies in prostate cancer. This will …
[HTML][HTML] Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer
W Devlies, F Handle, G Devos, S Joniau, F Claessens - Cancers, 2021 - ncbi.nlm.nih.gov
Prostate cancer is an androgen-driven tumor. Different prostate cancer therapies
consequently focus on blocking the androgen receptor pathway. Clinical studies reported …
consequently focus on blocking the androgen receptor pathway. Clinical studies reported …
Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer.
W Devlies, F Handle, G Devos, S Joniau, F Claessens - Cancers, 2021 - europepmc.org
Prostate cancer is an androgen-driven tumor. Different prostate cancer therapies
consequently focus on blocking the androgen receptor pathway. Clinical studies reported …
consequently focus on blocking the androgen receptor pathway. Clinical studies reported …
Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer
W Devlies, F Handle, G Devos, S Joniau… - …, 2021 - pubmed.ncbi.nlm.nih.gov
Prostate cancer is an androgen-driven tumor. Different prostate cancer therapies
consequently focus on blocking the androgen receptor pathway. Clinical studies reported …
consequently focus on blocking the androgen receptor pathway. Clinical studies reported …
Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer.
W Devlies, F Handle, G Devos, S Joniau, F Claessens - Cancers, 2021 - europepmc.org
Prostate cancer is an androgen-driven tumor. Different prostate cancer therapies
consequently focus on blocking the androgen receptor pathway. Clinical studies reported …
consequently focus on blocking the androgen receptor pathway. Clinical studies reported …